

27 Feb 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: big pharma hunts for RNA tech; new data to boost Enhertu in breast cancer; positive pipeline news for Bayer; biosimilars reach a turning point; and *Scrip Asks* experts about prospects for pharma science and technology in 2022.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 25 February 2022, including: big pharma hunts for RNA tech; new data to boost Enhertu in breast cancer; positive pipeline news for Bayer; biosimilars reach a turning point; and *Scrip Asks* experts about prospects for pharma science and technology in 2022.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Big Pharma Deal Hunters Target RNA Approaches In Race To Build Best Platforms](#)" - Scrip, 21 Feb, 2022.)

(Also see "[AstraZeneca and Daiichi Sankyo's Enhertu Eyes 50% Of Breast Cancer Market Following HER2-Low Data](#)" - Scrip, 21 Feb, 2022.)

(Also see "[Bayer's Faith In Pharma Pipeline Paying Off](#)" - Scrip, 21 Feb, 2022.)

(Also see "[A US Biosimilar Turning Point Approaches, With Work To Do](#)" - Scrip, 17 Feb, 2022.)

(Also see "[*Scrip Asks...What Does 2022 Hold For Biopharma? Part 3: Technology And Science*](#)" - Scrip, 17 Feb, 2022.)

[Click here to explore this interactive content online](#) ✎